Selected pretreatment clinical and hematologic characteristics and treatment outcome of AML patients with a complex karyotype defined by the presence of 3 or 4 or at least 5 abnormalities6-150
| No. of abnormalities . | No. of patients . | Median age, y . | % patients younger than 60 y . | Median WBC, × 109/L . | % CR . | P6-151 . | 5-y CIR (SE) . | P6-151 . | % (95% CI) 5-y OS . | P6-151 . |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 or 4 | 36 | 51 | 58 | 10.8 | 47 | .02 | 0.88 (0.09) | .002 | 8 (3-20) | .002 |
| 5 or more | 99 | 64 | 33 | 7.3 | 30 | <.001 | 0.97 (0.04) | <.001 | 2 (1-6) | <.001 |
| P6-152 | NA | .02 | .01 | .30 | .10 | NA | .04 | NA | .004 | NA |
| No. of abnormalities . | No. of patients . | Median age, y . | % patients younger than 60 y . | Median WBC, × 109/L . | % CR . | P6-151 . | 5-y CIR (SE) . | P6-151 . | % (95% CI) 5-y OS . | P6-151 . |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 or 4 | 36 | 51 | 58 | 10.8 | 47 | .02 | 0.88 (0.09) | .002 | 8 (3-20) | .002 |
| 5 or more | 99 | 64 | 33 | 7.3 | 30 | <.001 | 0.97 (0.04) | <.001 | 2 (1-6) | <.001 |
| P6-152 | NA | .02 | .01 | .30 | .10 | NA | .04 | NA | .004 | NA |
WBC indicates white blood cell count; NA, not applicable. Other abbreviations are explained in the footnote to Table 5.
Patients with t(8;21), inv(16)/t(16;16), and t(9;11) excluded.
For comparison with normal cytogenetics.
For comparison of 3 or 4 abnormalities with 5 or more abnormalities.